Hull York Medical School
Philip Beer currently serves as the Chief Scientific Officer and Vice President, Head of Research and Translational Medicine at Step Pharma since July 2021, focusing on developing novel therapeutics targeting CTP Synthase 1. Additionally, Philip holds the position of Honorary Professor in Translational Medicine at Hull York Medical School and chairs the Genomics Working Group for the British In Vitro Diagnostics Association. With extensive experience in clinical cancer genomics, including supporting major genomic projects and serving as a Consultant Haematopathologist, Philip has also founded Gabriel Precision Oncology and collaborates with institutions like Mayo Clinic and Wellcome Sanger Institute on cancer research. Previous roles include Head of Research and Translational Medicine at Karus Therapeutics and participation in various cancer clinical and research initiatives. Philip earned degrees from the University of Cambridge and the University of Nottingham, while also being associated with prestigious professional bodies such as the Royal College of Pathologists and the Royal College of Physicians.
This person is not in the org chart
Hull York Medical School
Hull York Medical School was founded in September 2003 as a partnership between the University of Hull, the University of York and the NHS in North and East Yorkshire and Northern Lincolnshire. Its first cohort of students graduated in 2008. The development and ethos of the school reflects innovative thinking about the kind of medical education required in the 21st century and a collaborative model of research development. Hull York Medical School provides a focus for improving the quality and equity of local health care and population health, the continuing professional development of all staff at all levels in the NHS, and assisting the NHS to retain newly qualified doctors. It is also the engine for the development of excellent medical and health research in the region.